Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novo Nordisk A/S (NYSE:NVO)

47.05
Delayed Data
As of Aug 29
 +0.16 / +0.34%
Today’s Change
45.80
Today|||52-Week Range
59.00
-18.99%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$91.9B

Company Description

Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care; and Biopharmaceuticals segments. The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related products, oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment handles the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation and other therapy areas. The company was founded in 1923 by August Krogh, Marie Krogh, Hans Christian Hagedorn, August Kongsted, Harald Pedersen, and Thorvald Pedersen and is headquartered in Bagsværd, Denmark.

Contact Information

Novo Nordisk A/S
Novo Allé
Bagsværd Capital Region 2880
P:(454) 444-8888
Investor Relations:
(453) 075-9085

Employees

Shareholders

Other institutional6.67%
Mutual fund holders2.88%
Individual stakeholders--

Top Executives

Lars Rebien SørensenPresident & Chief Executive Officer
Jesper BrandgaardChief Financial Officer & Executive Vice President
Mads Krogsgaard ThomsenChief Science Officer & Executive Vice President
Alan C. MosesGlobal Chief Medical Officer
Lars Fruergaard JørgensenChief of Staff & Executive Vice President